Stock Evaluator: DBV Technologies S.A. (DBVT)

DBV Technologies S.A. DBVT

$10.29 -0.36 -3.38%
October 29, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,033,825
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Commentary & Analysis


Financial Summary

Share Statistics DBVT Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $627.0 $232.8 40%
Shares Out (Mil) 433.5 53.4 87%
Institutional Ownership 99.9% 92.9% 96%
Float (Mil) 159.5 41.2 70%
Beta -0.21 0.96 3%
Avg Daily Volume (000s) 438 490 57%
Price Change
(52-week)
(33.4%) 48.2% 28%
Growth DBVT Industry
Median
Percentile
(All Stocks)
Sales (5yr) (13.1%) 12.8% 4%
Net Income (5yr) 1.6% (10.1%) 42%
EPS (5yr) 18.6% 15.8% 66
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 80.8% (15.7%) 97%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 4 4
Current EPS ($0.165) ($0.489) ($0.488)
Month Ago EPS ($0.162) ($0.383) ($0.163)
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS ($0.162) ($0.383) ($0.163)
Year/Year Chg 42.2% (53.6%) (90.5%)
Financials DBVT Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $5 $37 6%
Net Income (TTM) (Mil) ($176) ($44) 7%
EPS (TTM) ($0.601) ($1.600) 26%
Operating Cash Flow (TTM) (Mil) ($169) ($33) 4%
Net Cash Flow (TTM) (Mil) $72 $2 74%
Long-Term Debt (Q1) (Mil) $7 $4 27%
Enterprise Value (Q1) (Mil) $632 $174 36%
Valuation DBVT Industry
Median
Percentile
(All Stocks)
P/B 19.72 2.22 95%
P/E na 20.8 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios DBVT Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 66.9% 96%
Net Margin na (75.3%) na
ROA (96.0%) (47.3%) 6%
ROE (142.7%) (53.3%) 6%
Liabilities to Assets 28.1% 29.4% 20%
F-Score 3 2 18%

DBV Technologies S.A. did not pass any screens on 10/28/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors